Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Signs on IDEC Pharmaceuticals as Database Subscriber

NEW YORK, Jan 8 – Gene Logic has signed on IDEC pharmaceuticals, a developer of antibody therapeutics, as a multi-year subscriber to its GeneExpress Oncology DataSuite, Gene Logic announced Monday.

IDEC will use the database to discover and develop cancer therapeutics. The database provides disease-specific gene expression profiles for a number of human cancer types . The system will be deployed, along with Gene Logic’s GX2000 software, throughout the company’s R&D unit.

Financial terms of the subscription agreement were not disclosed.

“We are very pleased to establish a partnership with IDEC Pharmaceuticals to support their focused research on cancer," Gene Logic CEO Mark Gessler said in a statement. " This partnership strengthens and further validates our ongoing strategy of delivering targeted solutions that address the specialized needs of our pharmaceutical and biotechnology customers as they pursue genomics-driven drug development initiatives."

Gene Logic has recently signed as subscribers to its databases Organon, Boehringer Ingelheim Pharmaceuticals, Biogen, Proctor & Gamble,

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.